DE60019106D1 - Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen - Google Patents

Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Info

Publication number
DE60019106D1
DE60019106D1 DE60019106T DE60019106T DE60019106D1 DE 60019106 D1 DE60019106 D1 DE 60019106D1 DE 60019106 T DE60019106 T DE 60019106T DE 60019106 T DE60019106 T DE 60019106T DE 60019106 D1 DE60019106 D1 DE 60019106D1
Authority
DE
Germany
Prior art keywords
disorders
environment
peptides
behavioral disorders
treating impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019106T
Other languages
English (en)
Other versions
DE60019106T2 (de
Inventor
Tony Marcel
Francois Rougeon
Catherine Rougeot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE60019106D1 publication Critical patent/DE60019106D1/de
Application granted granted Critical
Publication of DE60019106T2 publication Critical patent/DE60019106T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60019106T 1999-06-23 2000-06-22 Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen Expired - Lifetime DE60019106T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23
US140563 1999-06-23
PCT/EP2000/006259 WO2001000221A2 (en) 1999-06-23 2000-06-22 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders

Publications (2)

Publication Number Publication Date
DE60019106D1 true DE60019106D1 (de) 2005-05-04
DE60019106T2 DE60019106T2 (de) 2006-02-16

Family

ID=22491816

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60019106T Expired - Lifetime DE60019106T2 (de) 1999-06-23 2000-06-22 Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60040878T Expired - Lifetime DE60040878D1 (de) 1999-06-23 2000-06-22 Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60040878T Expired - Lifetime DE60040878D1 (de) 1999-06-23 2000-06-22 Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen

Country Status (14)

Country Link
US (2) US7387778B2 (de)
EP (2) EP1593387B1 (de)
JP (1) JP2003512302A (de)
CN (1) CN1189211C (de)
AT (2) ATE414529T1 (de)
AU (1) AU6154700A (de)
CA (1) CA2376935A1 (de)
CY (1) CY1108745T1 (de)
DE (2) DE60019106T2 (de)
DK (2) DK1185294T3 (de)
ES (2) ES2238299T3 (de)
NZ (1) NZ516477A (de)
PT (2) PT1593387E (de)
WO (1) WO2001000221A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
NZ516477A (en) 1999-06-23 2004-02-27 Pasteur Institut Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP1216707B1 (de) * 2000-12-22 2005-02-09 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2350123T3 (es) 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
EP1577320B1 (de) 2004-03-19 2012-07-18 Institut Pasteur Von humanen BPLP Proteinen abgeleitete Peptide, deren kodierende Polynukleotide und Antikörper gegen besagte Peptide
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2720778C (en) 2008-04-07 2017-10-17 Institut Pasteur Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopeptidases
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
DE102009039655B3 (de) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
NZ516477A (en) 1999-06-23 2004-02-27 Pasteur Institut Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP1216707B1 (de) 2000-12-22 2005-02-09 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden

Also Published As

Publication number Publication date
WO2001000221A3 (en) 2001-05-03
PT1185294E (pt) 2005-08-31
DE60040878D1 (de) 2009-01-02
ATE414529T1 (de) 2008-12-15
US7387778B2 (en) 2008-06-17
ATE291927T1 (de) 2005-04-15
JP2003512302A (ja) 2003-04-02
US20030078200A1 (en) 2003-04-24
CN1356906A (zh) 2002-07-03
EP1593387A1 (de) 2005-11-09
US20030186870A1 (en) 2003-10-02
ES2238299T3 (es) 2005-09-01
PT1593387E (pt) 2009-03-18
AU6154700A (en) 2001-01-31
CA2376935A1 (en) 2001-01-04
DE60019106T2 (de) 2006-02-16
EP1593387B1 (de) 2008-11-19
CY1108745T1 (el) 2014-04-09
DK1593387T3 (da) 2009-03-02
CN1189211C (zh) 2005-02-16
EP1185294A2 (de) 2002-03-13
NZ516477A (en) 2004-02-27
DK1185294T3 (da) 2005-08-01
WO2001000221A2 (en) 2001-01-04
EP1185294B1 (de) 2005-03-30
ES2315753T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
DE60019106D1 (de) Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
WO2004019884A3 (en) Agents and methods for enhancing bone formation
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DE69905878T2 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition